Proceeds from recent exercise of warrants estimated to extend cash runway into mid Q1 2025, including interim data readout from Phase 2a biomarker study of lead program, GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF)

最近行使认股权证的收益估计将延长现金跑道至2025年第一季度中期，包括lead项目GRI-0621治疗特发性肺纤维化（IPF）的2a期生物标志物研究的中期数据读数

Current treatment options for IPF are limited with only 2 approved drugs which have significant side-effects, limited compliance and no impact on survival

目前IPF的治疗选择有限，只有2种批准的药物具有明显的副作用，依从性有限且对生存没有影响

LA JOLLA, CA, Oct. 24, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that on October 22, 2024 it closed its previously announced transaction involving the exercise of certain existing warrants to purchase an aggregate of 762,236 shares of the Company’s common stock originally issued by GRI Bio in February 2024..

加利福尼亚州拉霍亚，2024年10月24日-GRI Bio，Inc.（纳斯达克：GRI）（“GRI Bio”或“公司”）是一家生物技术公司，致力于开发用于治疗炎症、纤维化和自身免疫性疾病的自然杀伤T（NKT）细胞调节剂的创新管道，今天宣布，2024年10月22日，它完成了之前宣布的交易，涉及行使某些现有认股权证，以购买GRI Bio于2024年2月最初发行的762236股公司普通股。

The gross proceeds to the Company from the exercise of warrants were approximately $0.8 million, prior to deducting placement agent fees and offering expenses payable by the Company. Including the gross proceeds from this offering, the Company has raised approximately $13.9 million in gross proceeds since the beginning of 2024..

在扣除公司应付的配售代理费和发行费用之前，公司行使认股权证的总收益约为80万美元。包括此次发行的总收益，自2024年初以来，该公司已筹集了约1390万美元的总收益。

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

H、 C.Wainwright&Co.担任此次发行的独家配售代理。

The shares of common stock issued upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-276205).

行使现有认股权证后发行的普通股股份根据表格S-1（文件号333-276205）中的有效登记声明进行登记。

Marc Hertz, PhD, Chief Executive Officer of GRI Bio, commented, “The proceeds from the financings we have completed since the start of this year have greatly strengthened our balance sheet and are estimated to have provided the necessary funding to advance the development of our lead program into the middle of the first quarter of 2025.

GRI Bio首席执行官马克·赫兹（MarcHertz）博士评论道：“自今年年初以来，我们完成的融资收益极大地加强了我们的资产负债表，预计将提供必要的资金，将我们的领先项目的发展推进到2025年第一季度中期。

With these proceeds in hand and the continued progress toward interim and topline data for our lead program, expected in the coming quarters, we believe we are well positioned to realize the full potential of GRI-0621 to provide significant benefit to IPF patients.”.

有了这些收益，以及在未来几个季度我们的领先项目的中期和顶线数据方面的持续进展，我们相信我们已经做好了充分的准备，可以充分发挥GRI-0621的潜力，为IPF患者提供显着的益处。”

In consideration for the immediate exercise of the existing warrants for cash, the Company issued new unregistered Series D-1 warrants to purchase up to an aggregate of 762,236 shares of the Company’s common stock and new unregistered Series D-2 warrants to purchase up to an aggregate of 762,236 shares of the Company’s common stock.

考虑到立即行使现有的现金认股权证，公司发行了新的未注册D-1系列认股权证，以购买总计762236股公司普通股，以及新的未注册D-2系列认股权证，以购买总计762236股公司普通股。

The new Series D-1 and D-2 warrants are immediately exercisable at an exercise price of $1.00 per share. The Series D-1 warrants will have a term of five years from the issuance date and the Series D-2 warrants will have a term of eighteen months from the issuance date..

新的D-1和D-2系列认股权证可立即以每股1.00美元的行权价格行权。D-1系列认股权证的有效期为自发行日起五年，D-2系列认股权证的有效期为自发行日起十八个月。

The new Series D-1 and D-2 warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Regulation D promulgated thereunder and, along with the shares of common stock issuable upon exercise of the new warrants, have not been registered under the Securities Act, or applicable state securities laws.

上述新的D-1和D-2系列认股权证是根据经修订的1933年《证券法》（“证券法”）第4（a）（2）节以及根据该法案颁布的D条例以私募方式发行的，并且与行使新认股权证时可发行的普通股股票一起，尚未根据《证券法》或适用的州证券法进行登记。

Accordingly, the new warrants issued in the private placement and the shares of common stock issuable upon the exercise of the new warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws..

因此，私募发行的新认股权证和行使新认股权证后可发行的普通股股份不得在美国发售或出售，除非根据有效的登记声明或《证券法》和此类适用的州证券法登记要求的适用豁免。

This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction..

本新闻稿不构成出售或招揽购买这些证券的要约，也不构成在根据任何州或其他司法管辖区的证券法进行注册或资格认证之前，在任何州或其他司法管辖区出售这些证券都是非法的。

About GRI Bio, Inc.

关于GRI Bio，Inc。

GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis.

。GRI Bio的疗法旨在针对NKT细胞的活性，NKT细胞是炎症级联反应早期的关键调节因子，可中断疾病进展并恢复免疫系统的体内平衡。

NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications.

NKT细胞是先天性T细胞，具有NK细胞和T细胞的共同特性，是先天性和适应性免疫反应之间的功能联系。1型不变（iNKT）细胞在炎症和纤维化适应症中观察到的损伤，炎症反应和纤维化的传播中起关键作用。

GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus.

GRI Bio的主要项目GRI-0621是iNKT细胞活性的抑制剂，正在开发作为治疗特发性肺纤维化的新型口服治疗剂，这是一种严重的疾病，其需求尚未得到满足。该公司还正在开发用于治疗系统性红斑狼疮的新型2型NKT激动剂管道。

Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline..

此外，GRI Bio拥有500多种专有化合物的库，能够为不断增长的管道提供燃料。

Forward-Looking Statements

前瞻性声明

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions.

本新闻稿包含1995年《私人证券诉讼改革法案》中“安全港”条款所指的“前瞻性声明”。前瞻性陈述可以通过使用诸如“预期”、“相信”、“沉思”、“可能”、“估计”、“预期”、“打算”、“寻求”、“可能”、“可能”、“计划”、“潜在”、“预测”、“项目”、“目标”、“目标”、“应该”、“将会”、“将会”等词语或这些词语或其他类似表达的否定词来识别。

These forward-looking statements are based on the Company’s current beliefs and expectations. Forward-looking statements include, but are not limited to, the Company’s expectations with respect to development and commercialization of the Company’s product candidates, the timing of initiation or completion of clinical trials and availability of resulting data, potential acceleration of enrollment, the potential benefits and impact of the Company’s clinical trials and product candidates and any implication that the data or results observed in preclinical trials or earlier studies or trials will be indicative of results of later studies or clinical trials, the Company’s beliefs and expectations regarding potential stakeholder value and future financial performance, the Company’s beliefs about the timing and outcome of regulatory approvals and potential regulatory approval pathways, the Company’s expected milestones for 2024 and 2025, including the potential availability of clinical trial data, and the Company’s beliefs and expectations regarding the sufficiency of its existing cash and cash equivalents to fund its operating expenses and capital expenditure requirements and its estimated cash runway.

这些前瞻性陈述基于公司当前的信念和期望。前瞻性陈述包括但不限于公司对公司候选产品的开发和商业化的预期，临床试验的开始或完成时间以及产生的数据的可用性，潜在的注册加速，公司临床试验和候选产品的潜在益处和影响，以及在临床前试验或早期研究或试验中观察到的数据或结果将指示后期研究或临床试验结果的任何暗示，公司对潜在利益相关者价值和未来财务业绩的信念和期望，公司对监管批准和潜在监管批准途径的时间和结果的信念，公司2024年和2025年的预期里程碑，包括临床试验的潜在可用性试验数据，以及公司对现有现金和现金等价物是否足以满足运营费用和资本支出要求以及预计现金周转的信念和期望。

Actual results may differ from the forward-looking statements expressed by the Company in thi.

实际结果可能与公司在thi中表达的前瞻性声明不同。

Investor Contact:

投资者联系人：

JTC Team, LLCJenene Thomas(908) 824-0775GRI@jtcir.com

裕廊集团有限责任公司团队Jenene Thomas（908）824-0775GRI@jtcir.com